Collegium (COLL) Q3 2026 Earnings Call Transcript
Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.
How this was made

The 30-second read
Why it matters
The earnings release provides fresh data on revenue growth, prescription trends, and capital allocation, offering traders a basis for short‑term positioning.
Market read
Earnings beat and buyback announcement give a clear catalyst for near‑term price movement.
What to watch
The $50M accelerated share repurchase could strain cash if future growth slows, and competition in ADHD space remains intense.
Background
Collegium (COLL) is a specialty pharmaceutical company focused on ADHD and pain treatments. The Q3 2026 call highlighted record revenue, product growth, and a new share repurchase program.
Ticker impact
Q3 2026 earnings call disclosed record $216.3M revenue, 3% YoY growth and reaffirmed full-year guidance plus a $50M accelerated share repurchase.
likely modest upside as the buyback and reaffirmed guidance support the share price
The company delivered record revenue, confirmed guidance, and announced a sizable share repurchase, all fresh primary disclosures that can move the stock.
Market effects
Strengthens the ADHD pharmaceutical niche and may lift peers with similar product pipelines.
U.S. biotech sector may see modest uplift from the earnings beat.
Limited to investors focused on specialty pharma and ADHD treatments.
Counterpoint
Guidance reaffirmation may already be priced in; the modest revenue growth could disappoint if expectations were higher.
Key entities
- CompanyCollegium
U.S. listed specialty pharma firm (ticker COLL).


